6 results match your criteria: "both at Duke University[Affiliation]"
Sequential Targeted Treatment for a Geriatric Patient with Acute Myeloid Leukemia with Concurrent FLT3-TKD and IDH1 Mutations.
Fed Pract
January 2021
is a Resident at Stanford University Medical Center, Department of Medicine in Stanford, California. is a Staff Physician and is a Fellow, both at Durham Veterans Affairs Medical Center in North Carolina. is a Staff Pathologist at Cleveland Clinic Foundation, Department of Pathology in Cleveland, Ohio. is a Staff Physician at Raymond G. Murphy New Mexico Veterans Affairs Medical Center, Section of Hematology and Oncology in Albuquerque, New Mexico. Daphne Friedman is an Associate Professor of Medicine and Sendhilnathan Ramalingam is a Fellow, both at Duke University Medical Center in Durham, North Carolina.
Targeting and monitoring several acute myeloid leukemia mutations sequentially provides insights into optimal treatment plans.
View Article and Find Full Text PDFWhy Accept a VA Detail or Short-Term Assignment? Benefits to Employees and the Service.
Fed Pract
November 2020
is Associate Chief of Staff (Ambulatory Care Service), and is a Staff Physician and Deputy Chief of the Office of Public Health/ Epidemiology, Public Health Liaison/ Community Support, both at the Durham VA Health Care System. Wendy Henderson is an Assistant Professor, and Genevieve Embree is a Medical Instructor in the Department of Medicine, both at Duke University in North Carolina.
Partners in Oncology Care: Coordinated Follicular Lymphoma Management.
Fed Pract
August 2019
is Associate Chief of Staff for Ambulatory Care; is a Staff Physician, Hematology-Oncology; and is 1F/1D Ambulatory Care Clinics-Chief, Clinical Pharmacy Specialist; all at Durham VA Medical Center in North Carolina. Wendy Henderson is an Assistant Professor, general internal medicine; and Daphne Friedman is an Associate Professor, medical oncology, both at Duke University in Durham, North Carolina.
Four case examples illustrate the important role of multidisciplinary medical care for the optimal long-term care of patients with follicular lymphoma.
View Article and Find Full Text PDFCE: Understanding the Complications of Sickle Cell Disease.
Am J Nurs
June 2019
Paula Tanabe is a professor in the Schools of Nursing and Medicine and associate dean for research development and data science at Duke University, Durham, NC. Regena Spratling is the associate dean and chief academic officer for nursing in the Byrdine F. Lewis College of Nursing and Health Professions, Georgia State University, Atlanta. Dana Smith is a clinical nurse II in the ICU, and Peyton Grissom is the clinical team lead on a general medicine step-down unit, both at Duke University Hospital, Durham, NC. Mary Hulihan is a health scientist in the Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta. Contact author: Mary Hulihan, The authors and planners have disclosed no potential conflicts of interest, financial or otherwise.
: Sickle cell disease (SCD) is an autosomal recessive genetic condition that alters the shape and function of the hemoglobin molecule in red blood cells. While the overall survival rate among children with SCD has improved in recent years, pediatric rates of hospitalization, ED use, and mortality from complications of SCD remain high. Among patients ages 18 and older, hospital admission and ED usage are even greater-and the median age at death of people with SCD is considerably lower than that of the general population.
View Article and Find Full Text PDFAccountable Care Reforms Improve Women's And Children's Health In Nepal.
Health Aff (Millwood)
November 2017
Mark McClellan ( ) is director of the Duke-Robert J. Margolis, M.D., Center for Health Policy and the Robert J. Margolis, M.D., Professor of Business, Medicine, and Policy, both at Duke University, in Durham, North Carolina, and Washington, D.C.
Over the past decade the Ministry of Health of Nepal and the nonprofit Possible have partnered to deliver primary and secondary health care via a public-private partnership. We applied an accountable care framework that we previously developed to describe the delivery of their integrated reproductive, maternal, newborn, and child health services in the Achham district in rural Nepal. In a prospective pre-post study, examining pregnancies at baseline and 541 pregnancies in follow-up over the course of eighteen months, we found an improvement in population-level indicators linked to reducing maternal and infant mortality: receipt of four antenatal care visits (83 percent to 90 percent), institutional birth rate (81 percent to 93 percent), and the prevalence of postpartum contraception (19 percent to 47 percent).
View Article and Find Full Text PDFStrategies For Assessing Delivery System Innovations.
Health Aff (Millwood)
March 2017
Mark McClellan is director of the Duke-Robert J. Margolis, MD, Center for Health Policy and the Robert J. Margolis, MD, Professor of Business, Medicine, and Health Policy, both at Duke University, in Durham, North Carolina, and Washington, D.C.
Driven by evidence of continuing gaps in health care quality and efficiency and inspired by the emergence of new value-based payment models, both large and small health care organizations are developing and deploying a wide range of care delivery innovations. But how can decision makers in these organizations determine if the innovations really improve service delivery, patient experience, clinical outcomes, or costs? Organization leaders need appropriate, timely evidence to inform their decision making. In this article we describe a range of approaches to evaluating innovations and pose key questions about the validity of the results.
View Article and Find Full Text PDF